UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Sphingosine Kinase 1 Inhibitor 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole Induces Proteasomal Degradation of Sphingosine Kinase 1 in Mammalian Cells

The Journal of biological chemistry, 2010-12, Vol.285 (50), p.38841-38852

2010

Volltextzugriff (PDF)

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

Haematologica (Roma), 2017-05, Vol.102 (5), p.843-853

2017

Volltextzugriff (PDF)

An oncogenic role for sphingosine kinase 2

Oncotarget, 2016-10, Vol.7 (40), p.64886-64899

2016

Volltextzugriff (PDF)

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

Leukemia & lymphoma, 2021-04, Vol.62 (5), p.1157-1166

2021

Volltextzugriff (PDF)

Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling

The Journal of experimental medicine, 2005-01, Vol.201 (1), p.49-54

2005

Volltextzugriff (PDF)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

PloS one, 2017-01, Vol.12 (1), p.e0168947

2017

Volltextzugriff (PDF)

Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

Leukemia & lymphoma, 2013-01, Vol.54 (1), p.198-201

2013

Volltextzugriff (PDF)

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Blood advances, 2019-05, Vol.3 (10), p.1610-1621

2019

Volltextzugriff (PDF)

Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity

The Journal of biological chemistry, 2008-04, Vol.283 (15), p.9606-9614

2008

Volltextzugriff (PDF)

Cellular signalling by sphingosine kinase and sphingosine 1‐phosphate

IUBMB life, 2006-08, Vol.58 (8), p.467-472

2006

Volltextzugriff (PDF)

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

British journal of haematology, 2019-08, Vol.186 (3), p.e56-e60

2019

Volltextzugriff (PDF)

Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

Blood, 2014-12, Vol.124 (21), p.4515-4515

2014

Volltextzugriff (PDF)

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

Blood, 2015-12, Vol.126 (23), p.596-596

2015

Volltextzugriff (PDF)

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Blood, 2015-12, Vol.126 (23), p.4841-4841

2015

Volltextzugriff (PDF)

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

Blood, 2015-12, Vol.126 (23), p.2770-2770

2015

Volltextzugriff (PDF)

Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1a and 1b

The international journal of biochemistry & cell biology, 2012-09, Vol.44 (9), p.1457-1464

2012

Volltextzugriff (PDF)

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

Blood, 2016-12, Vol.128 (22), p.3957-3957

2016

Volltextzugriff (PDF)

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

Blood, 2013-11, Vol.122 (21), p.2705-2705

2013

Volltextzugriff (PDF)

MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients

Blood, 2013-11, Vol.122 (21), p.4985-4985

2013

Volltextzugriff (PDF)

Validation of nanostring microrna analysis in leukaemic blood

Pathology, 2014, Vol.46, p.S93-S93

2014

Volltextzugriff (PDF)

Sphingosine Kinases: Biochemistry, Regulation, and Roles

Lysophospholipid Receptors, 2013, p.153-183

2013

Volltextzugriff (PDF)

Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling

The Journal of cell biology, 2005, Vol.168 (2)

2005

Volltextzugriff (PDF)

Personalized Medicine Support System : Resolving Conflict in Allocation to Risk Groups and Predicting Patient Molecular Response to Targeted Therapy

Health Informatics - An International Journal, 2017-05, Vol.6 (2), p.1-21

2017

Volltextzugriff (PDF)

Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

Clinical cancer research, 2023-11, Vol.29 (21), p.4449-4463

2023

Volltextzugriff (PDF)

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Blood, 2023-11, Vol.142 (Supplement 1), p.1619-1619

2023

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)
Buchkapitel
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Sphingosine Kinase 1 Inhibitor 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole Induces Proteasomal Degradation of Sphingosine Kinase 1 in Mammalian Cells

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

An oncogenic role for sphingosine kinase 2

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib

Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity

Cellular signalling by sphingosine kinase and sphingosine 1‐phosphate

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

High Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells

Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: Functional differences between sphingosine kinase 1a and 1b

In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy

STAT5 Is a Critical Component Of The Time-Dependent Sensitivity Of CML Cells To TKI Treatment In a Bcr-Abl-Dependent, But JAK2-Independent Manner

MicroRNA Dysregulation in Newly Diagnosed Chronic Myeloid Leukaemia Patients

Validation of nanostring microrna analysis in leukaemic blood

Sphingosine Kinases: Biochemistry, Regulation, and Roles

Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling

Personalized Medicine Support System : Resolving Conflict in Allocation to Risk Groups and Predicting Patient Molecular Response to Targeted Therapy

Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

Molecular Mechanisms Underlying Response and Resistance to Glofitamab

Suchergebnisse filtern